Leukemia: all 5,475 studies
Page 27 of 55. Open to participants first (629), then studies with results posted, then the rest; newest registration first within each.
- A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic MalignanciesCompletedNCT03886831Phase 1
- VPA Expanded UCB Transplantation for Treatment of Patients With Hematological MalignanciesCompletedNCT03885947Phase 1
- Precision Dosing of Tyrosine Kinase Inhibitors in CML PatientsCompletedNCT03885830
- Gamma Delta T Cells in AMLStatus unknownNCT03885076
- Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK InhibitorWithdrawnNCT03884972Phase 1
- A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDSTerminatedNCT03884829Phase 1
- A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I MutationStatus unknownNCT03883100Phase 2
- Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid LeukemiaCompletedNCT03882281Phase 1
- Investigation of the Gut Microbiota in Patients With Acute Myeloid LeukemiaCompletedNCT03881826Not applicable
- Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell MalignanciesStatus unknownNCT03881774Phase 1
- Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene MutationWithdrawnNCT03881735Phase 2
- Real-World Data Study Focused on Chronic Lymphocytic Leukemia (CLL) Patient Treatment Options and Their EffectivenessStatus unknownNCT03881592
- CPX-351+GO in Subjects 55 Years Old, or Older, With AMLTerminatedNCT03878927Phase 1
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
- Respiratory Training in Patients With LeukemiaCompletedNCT03876834Not applicable
- A Study to Assess Effectiveness of Venclexta (Venetoclax) in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia in Routine Clinical Practice in Russian FederationCompletedNCT03873857
- Assessment of Financial Difficulty in Participants with Chronic Lymphocytic Leukemia and Multiple MyelomaCompletedNCT03870633
- Ex Vivo Drug Sensitivity Testing and Mutation ProfilingCompletedNCT03860376
- CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic LeukemiaStatus unknownNCT03854994Phase 1
- Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic LeukemiaWithdrawnNCT03851081Phase 1/2
- Bendamustine and Rituximab (BR) as Induction and Maintenance in Relapsed and Refractory Chronic Lymphocytic LeukemiaStatus unknownNCT03847727
- A Prospective Multicenter Clinical Trial of MRD-based Treatment Strategy in Children and Young Adults With AMLStatus unknownNCT03846362Phase 3
- Senl_1904A and Senl_1904B Chimeric Antigen Receptor （CAR） T-Cell in the Treatment of r/ r Acute B Lymphocytic LeukemiaStatus unknownNCT03840317Phase 1
- Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLLActive, not recruitingNCT03836261Phase 3
- A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)CompletedNCT03833180Phase 1
- Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From DiagnosisCompletedNCT03831776Phase 2
- Nalbuphine Versus Morphine for Mucositis Pain in Pediatric Cancer PatientsCompletedNCT03825887Phase 3
- CPX-351 Plus Enasidenib for Relapsed AMLActive, not recruitingNCT03825796Phase 2
- The Effects of AMPC in the Treatments of Refractory or Relapsed AMLStatus unknownNCT03825146Phase 1
- Blinatumomab Expanded T-cells (BET) in Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic LeukemiaStatus unknownNCT03823365Phase 1
- Evaluate Efficacy and Safety/Tolerability Profiles of Antroquinonol in Acute Myeloid Leukemia (AML) Adult PatientsCompletedNCT03823352Phase 2
- SCT in Ph Positive Acute Lymphoblastic LeukemiaCompletedNCT03821727
- Bisantrene for Relapsed /Refractory AMLCompletedNCT03820908Phase 2
- Effect of Food on Blood Levels of ASTX727CompletedNCT03813186Phase 1
- Immunotherapy With CD19 CAR T-cells in Patients With Relapsed or Refractory CD19+ Leukemia and LymphomaCompletedNCT03811457Not applicable
- Study in Patients With Chronic LeukemiaTerminatedNCT03807479Phase 2
- Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell TransplantWithdrawnNCT03807063Phase 1
- Feasibility of Partners in Care Program for Caregivers of Patients With Acute Myeloid LeukemiaTerminatedNCT03806192Not applicable
- The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir AlafenamideTerminatedNCT03804372Phase 2
- Clinical Significance of Occult Central Nervous System Disease In Adult Acute Lymphoblastic LeukemiaCompletedNCT03803670
- Decitabine Plus mBU/CY Preconditioning for Relapse/Refractory Acute LeukemiaStatus unknownNCT03799224Phase 2/3
- Human CD19 Targeted T Cells Injection Therapy for Relapsed and Refractory CD19-positive LeukemiaStatus unknownNCT03798509Phase 1
- Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic LeukemiaStatus unknownNCT03796390Phase 1
- CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic MalignanciesStatus unknownNCT03795779Early Phase 1
- A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk TranslocationsCompletedNCT03793140Phase 2
- Ex-vivo Expanded γδ T-lymphocytes (OmnImmune®) in Patients With Acute Myeloid Leukaemia (AML)CompletedNCT03790072Phase 1
- Exploring Disease Immunogenicity and the Immunological Effects of Hypomethylating Agents in Acute Myeloid LeukemiaActive, not recruitingNCT03789981
- A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic SyndromeCompletedNCT03787498Phase 1
- AZD6738 for Patients With Progressive MDS or CMMLActive, not recruitingNCT03770429Phase 1
- Lentivirally Redirected CD123 Autologous T Cells in AMLTerminatedNCT03766126Phase 1
- Dexamethasone in Refractory or First Relapsed Acute Myeloid LeukemiaTerminatedNCT03765541Phase 3
- Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute LeukemiasTerminatedNCT03761069Phase 1
- Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT03760523Phase 1
- HDM201 Added to CT in R/R or Newly Diagnosed AMLWithdrawnNCT03760445Phase 1/2
- Cardiovascular Function in Acute LeukemiaCompletedNCT03760237
- Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic LeukemiaCompletedNCT03755947Phase 2
- Long-term Outcomes for Acute Myeloid Leukemia PatientsStatus unknownNCT03755856
- Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic LeukemiaTerminatedNCT03755154Phase 1
- TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid LeukemiaWithdrawnNCT03752138Phase 1
- Long-term Safety Study of Arsenic Trioxide in Newly Diagnosed, Low-to-intermediate Risk Acute Promyelocytic LeukemiaStatus unknownNCT03751917
- Expanded Treatment Protocol for Adults With FLT3-ITD Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) to Receive QuizartinibNo longer availableNCT03746912
- Evaluation of a Cardiovascular Active Prevention in Chronic Myeloid Leukemia on the Cardiovascular Morbi-mortalityTerminatedNCT03746054Phase 3
- Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaWithdrawnNCT03745352Phase 2
- Expression of Aberrant CD Markers in Acute Leukemia:Retrospective Study in South Egypt Cancer InstituteStatus unknownNCT03743909
- REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic LeukemiaTerminatedNCT03742323Phase 1/2
- Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood CancerWithdrawnNCT03739606Phase 2
- CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLLCompletedNCT03739554Phase 1
- Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I TrialTerminatedNCT03735446Phase 1
- Microbiota Changes in Acute Myeloid Leukemia Patients Undergoing Intensive ChemotherapyCompletedNCT03728699
- Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)CompletedNCT03723681Phase 1
- A Study to Evaluate Ibrutinib Retention in Chronic Lymphocytic Leukemia Participants Treated in a Real World SettingCompletedNCT03720561
- A Study of Perpetrator Drug Interactions of Enasidenib in AML PatientsCompletedNCT03720366Phase 1
- Haplo HCT vs Haplo-cord HCT for Patients With AMLCompletedNCT03719534Phase 3
- Comparison of Diagnostic Yield Among M-FISH, FISH Probe Panel and Conventional Cytogenetic Analysis in AMLCompletedNCT03719183
- Prognostic Values of Next Generation Sequencing (NGS) in Acute Myeloid Leukemia Patients With Allo-HSCTStatus unknownNCT03715621
- Blinatumomab in High-risk B-cell Precursor Acute Lymphoblastic LeukemiaActive, not recruitingNCT03709719Phase 2
- Iclusig PMS in CML or Ph+ALL PatientsStatus unknownNCT03709017
- Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLLTerminatedNCT03708003Phase 2
- Actinium-225-Lintuzumab in Patients With Acute Myeloid LeukemiaWithdrawnNCT03705858Phase 1
- International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic LeukaemiaTerminatedNCT03705507Phase 1/2
- Eltrombopag Used in Thrombocytopenia After Comsolidation Therapy in AMLStatus unknownNCT03701217Phase 2/3
- Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)WithdrawnNCT03699384Phase 1/2
- Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid LeukaemiaActive, not recruitingNCT03697707Phase 2
- IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCTTerminatedNCT03696537Phase 1
- A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AMLTerminatedNCT03690154Phase 1
- Midostaurin Associated With Standard Chemotherapy in Patients With Core-binding Factor LeukemiaTerminatedNCT03686345Phase 2
- CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCTStatus unknownNCT03685786Phase 1
- CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or LymphomaActive, not recruitingNCT03684889Phase 1
- Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute LeukemiaTerminatedNCT03672851Phase 1
- Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia.CompletedNCT03672695Phase 1
- CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.Status unknownNCT03671460Phase 1
- Efectiveness of Donor IL-15-stimulated NK Cells Post Transplant Infusion in in Acute LeukemiaCompletedNCT03669172Phase 1/2
- Asparaginase Activity Monitoring (AAM) in Adult Patients With Acute Lymphoblastic Leukemia (ALL)TerminatedNCT03668392Phase 2
- The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AMLStatus unknownNCT03665480Phase 2/3
- The Impact of Exercise Approaches on Sleep in Children With Acute Lymphoblastic LeukemiaCompletedNCT03664947Not applicable
- HMA+DLI vs DLI Preemptive Therapy Based on MRD for AL Undergoing Allo-HSCTStatus unknownNCT03662087Phase 2/3
- A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) Patients in Routine Clinical PracticeSuspendedNCT03659669
- Study of the Outcome of Patients With Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Receiving Iron Chelation Therapy After Allogeneic Hematopoietic Stem Cell TransplantationStatus unknownNCT03659084
- HLA 10/10 Matched Unrelated Donor vs Haploidentical Allogenic Hematopoietic Stem Cell TransplantationStatus unknownNCT03655145Phase 3
- CALLS: CML and Ph+ALL Low Level Mutation Prevalence SurveyCompletedNCT03647215